Floatz Rating
BB67/100
Confidence
Indicative
Sponsor
RTOG Foundation, Inc.
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
60High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02386826CT.gov INC280 Combined With Bevacizumab in Patients With Glioblastoma Multiforme | — | Completed | — | — | — |
NCT02186509CT.gov Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | — | Completed | — | — | — |
NCT02052648CT.gov Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors | — | Completed | — | — | — |
NCT01837862CT.gov A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas | — | Completed | — | — | — |
NCT01814813CT.gov Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | — | Terminated | — | — | — |
NCT01648348CT.gov Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT01609790CT.gov Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | — | Completed | — | — | — |
NCT01378481CT.gov High-Dose Vorinostat and Fractionated Stereotactic Body Radiation Therapy in Treating Patients With Recurrent Glioma | — | Terminated | — | — | — |
NCT01339039CT.gov Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma | — | Terminated | — | — | — |
NCT01498328CT.gov A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT01189240CT.gov RO4929097and Bevacizumab in Treating Patients With Progressive or Recurrent Malignant Glioma | — | Terminated | — | — | — |
NCT00879437CT.gov Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma | — | Completed | — | — | — |
NCT00731731CT.gov Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00641706CT.gov Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
NCT00667394CT.gov Tandutinib Plus Bevacizumab to Treat Recurrent Brain Tumors | — | Completed | — | — | — |
NCT00525525CT.gov Study of Bevacizumab Plus Temodar and Tarceva in Patients With Glioblastoma or Gliosarcoma | — | Completed | — | — | — |
NCT00268385CT.gov Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas | — | Active Not Recruiting | — | — | — |
NCT00238303CT.gov Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Gliosarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| (+)-Vincristine (this asset) | RTOG Foundation, Inc. | P3 | BB · 67 |
| Cediranib | Northwestern University | P2 | BBB |
| Temsirolimus | National Cancer Institute (NCI) | P2 | BBB |
| Gefitinib | National Cancer Institute (NCI) | P2 | BB |
| Sorafenib | University Hospital, Geneva | P2 | BB |
| 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- | National Cancer Institute (NCI) | P2 | BB |
| Tandutinib | National Cancer Institute (NCI) | P2 | BB |
| Vorinostat | National Cancer Institute (NCI) | P2 | BB |
| Irinotecan | RTOG Foundation, Inc. | P3 | BB |
+42 more in the Gliosarcoma cohort
Other indications for (+)-Vincristine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Mycosis Fungoides | — | P4 | BBB · 78 |
| Anaplastic Large Cell Lymphoma | — | P4 | BBB · 78 |
| Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | — | P4 | BBB · 77 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CediranibNorthwestern UniversityBBB
- TemsirolimusNational Cancer Institute (NCI)BBB
- GefitinibNational Cancer Institute (NCI)BB
- SorafenibUniversity Hospital, GenevaBB
- 2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)BB
Citation
Floatz Terminal. (+)-Vincristine in Gliosarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/vincristine-gliosarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →